Human Immune Response to COVID-19 Infection and Potential Role of Chloroquine Family of Drugs

De Groot, R.J.; Baker, S.C.; Baric R.S.; Brown, C.S.; Drosten, C.; Enjuanes, L. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol 2013, 87, 7790–7792.

Rothan, H.A.; Byrareddy, S.N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of autoimmunity 2020, 102433.

Li, Q.; Guan, X.; Wu, P.; Wang, X.; Zhou, L.; Tong, Y.; et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020.

Jin, Y.H.; Cai, L.; Cheng, Z.S.; Cheng, H.; Deng, T.; Fan, YP; et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020, 7:4.

Xu, Z.; Shi, L.; Wang, Y.; Zhang, J.; Huang, L.; et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine 2020.

Guan, W.J.; Ni Z.Y; Hu Y.; Liang W.H.; Ou, C.Q, et al. Clinical characteristics of coronavirus disease 2019 in China. The New England Journal of Medicine. 2020.

Mizumoto, K.; Kagaya, K.; Zarebski, A.; Chowel, l.G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro surveillance 2020, 25.

Ganyani, T.; Kremer. C.; Chen, D.; Torneri, A.; Faes, C.; Wallinga, J.; et al. Estimating the generation interval for COVID-19 based on symptom onset data. 2020. Available from: https://www.medrxiv.org/.

Yang, X.; Yu, Y.; Xu, J.; Shu, H.; Xia, J.; Liu, H.; et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med 2020.

Hoffmann, M.; Kleine-Weber, H.; Krüger, N.; Müller, M.; Drosten, C.; Pöhlmann, S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. Bio Rxiv. 2020.

Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395,497–506.

Zou, L.; Ruan, F.; Huang, M.; Liang, L.; Huang, H.; Hong, Z.; et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020.

Gorbalenya, A.E.; Baker, S.C.; Baric, R.S.; de Groot, R.J.; Drosten, C.; Gulyaeva, A.A.Severe acute respiratory syndrome-related coronavirus: the species and its viruses – a statement of the Coronavirus Study Group. bioRxiv 2020. https://www.biorxiv.org/content/10.1101/2020.02.07.937862v1

Lu, H.; Stratton, C.W.; Tang, Y.W. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol 2020, 92, 401–402.

Lai, C.C.; Shih, T.P.; Ko, W.C.; Tang, H.J. Hsueh P.R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int. J. Antimicrob. Agents 2020, 55.

McCloskey, B.; Heymann, D.L. SARS to novel coronavirus: old lessons and new lessons. Epidemiol. Infect 2020, 22, e22

Wilder-Smith, A.; Chiew, C.J.; Lee, V.J. Can we contain the COVID-19 outbreak with the same measures as for SARS? Lancet Infect. Dis 2020, doi: 10.1016/S1473-3099(20)30129-8.

Vincent, MJ; Bergeron, E.; Benjannet, S.; et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005, 2(69), 1-10. doi:10.1186/1743-422X-2-69

Savarino, A.; Boelaert, JR.; Cassone, A.; Majori, G.; Cauda, R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis 2003, 3(11), 722-727.

Gao, J.; Tian, Z.; Yang, X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020, 14, 72 -73

Colson, P.; Rolain, J.M.; Lagier, J.C.; Brouqui, P.; Raoult, D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020, 105932

Zhou, D.; Dai, S.M.; Tong, Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020.

Su, S.G.; Wong, W.; Shi, et al. Epidemiology, Genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 2016, 24, 490-502. https://doi.org/10.1016/j.tim.2016.03.003.

Chan, J.F.; To, K.K.; Tse, H.; Jin, D.Y.; Yuen, K.Y. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol 2013, 21, 544-55.

Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; et al. A Novel Coronavirus from Patients with Pneumonia in China 2019. The New England journal of medicine. 2020.

Schoeman, D.; Fielding, B.C. Coronavirus envelope protein: current knowledge. Virol J 2019, 16; 69. https://doi.org/10.1186/s12985-019-1182-0.

Gupta, M.K.; Vemula, S.; Donde, R.; Gouda, G.; Behera, L.; Vadde, R. In silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel. Journal of Biomolecular Structure and Dynamics 2020, https://doi.org/10.1080/07391102.2020.1751300.

Belouzard, S.; Chu, V.C.; Whittaker, G.R. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc. Natl. Acad. Sci. U.S.A. 106 2009, 5871, e5876, https://doi.org/10.1073/pnas.0809524106.

Van Hemert, M.J.; Van Den Worm, S. H. E.; Knoops, K.; Mommaas, A. M.; Gorbalenya, A.E.; Snijder, E.J. SARS-coronavirus replication/transcription complexes are membrane-protected and need a host factor for activity in vitro. PLoS Pathogens 2008, 4(5), e1000054, https://doi.org/10.1371/journal.ppat.1000054

Song, H. C.; Seo, M.Y.; Stadler, K.; Yoo, B.J.; Choo, Q.L.; Coates, S.R.; Uematsu, Y.; Harada, T.; Greer, C. E.; Polo, J. M.; Pileri, P.; Eickmann, M.; Rappuoli, R.; Abrignani, S.; Houghton, M.; Han, J. H. Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. Journal of Virology 2004, 78(19), 10328–10335, https://doi.org/10.1128/JVI.78.19.10328-10335. 2004.

Masters, P.S. The molecular biology of coronaviruses. Advances in Virus Research, 2006, 65(06),193–292. https://doi.org/10.1016/S0065-3527(06)66005-3.

Wrapp, D.; Wang, N.; Corbett, K.S.; Goldsmith, J.A.; Hsieh, C.L.; Abiona, O.; et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science (New York, NY) 2020.

Huang, Q.; Herrmann, A. Fast assessment of human receptor binding capability of 2019 novel coronavirus (2019-nCoV). Preprint. Posted online February 04, 2020. bioRxiv 930537.

Coutard, B.; Valle, C.; de Lamballerie, X.; Canard, B.; Seidah, N.G.; Decroly, E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res 2020, 176, 104742, https://doi.org/10.1016/j.antiviral.2020.104742.

Jacques, F.; Coralie, D.S.; Henri, C.; Nouara Y. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection, International Journal of Antimicrobial Agents 2020, doi: https://doi.org/10.1016/j.ijantimicag.2020.105960.

Mason, R.J. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J 2020, 55, 2000607 [https://doi.org/10.1183/13993003.00607-2020].

Wan Y.; Shang J.; Graham, R.; et al. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J Virol 2020, 94, e00127-20.

Tang, N.L.; Chan, P.K.; Wong, C.K.; et al. Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome. Clin Chem 2005, 51, 2333–2340.

Hancock, A.S.; Stairikerm, C.J.; Boesteanu, A.C.; et al. Transcriptome analysis of infected and bystander type 2 alveolar epithelial cells during influenza A virus infection reveals in vivo Wnt pathway downregulation. J Virol 2018, 92, e01325-18.

Mossel, E.C.; Wang, J.; Jeffers, S.; et al. SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells. Virology 2008, 372, 127–135.

Janeway, C.A.; Travers, P.; Walport, M.; Shlomchik, M. J. Immunobiology (5th ed.). New York and London: Garland Science. 2001, ISBN 0-8153-4101-6.

Parkin, J.; Cohen, B. An overview of the immune system. Lancet 2001, 357, 1777-89.

Stranford, Sharon A.; Jones, Patricia P.; Owen, J.A. (Eighth ed.). New York. Kuby immunology 1992, ISBN 978-1-4641-8978-4. OCLC 1002672752.

Huston, D.P. The biology of the immune system. JAMA 1997, 278, 1804–1814. [PubMed: 9396641]

Bretscher, P.; and Cohn, M. A theory of nonself discrimination. Science (Wash.D. C.) 1970, 169, 1042.

Delves, P.J.; Roitt, D.; The Immune System – First of two parts. N Engl J Med 2000, 343, 37-50.

Fengyan, Yu.; Herui, Yao.; Pengcheng, Zhu.; Xiaoqin, Zhang.; Qiuhui, Pan.; Chang, Gong.; Yijun Huang.; Xiaoqu, Hu.; Fengxi, Su.; Judy, Lieberman.; Erwei, Song. Let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells. Cell 2007, l 131, 1109–1123.

Kaminski, NE.; Faubert, K.B.L.; Holsapple, M.P. Toxic responses of the immune system. In: Casarett and Doull’s Toxicology. The Basic Science of Poisons. Edited by Klassen C.D. Seventh Edition, McGraw-Hill Medical Publishing Division, USA 2008; 485-556.

Elgert, K.D. Immunology: Understanding the Immune System. Blacksburg, VA: Virginia Tech Biology Department 1994, 1-418.

Tizard, I. Veterinary Immunology. Philadelphia, PA: W.B. Saunders Co. 1997, 5(1)-175.

Janeway, C.A.; Medzhitov, R. Innate immunity recognition. Annu Rev Immunol 2002, 20, 197-216.

Medzhitov, R.; Jane way, C. Jr. Innate immune recognition: Mechanisms and pathways. Immunol Rev 2000a, 173, 89-97.

Bals R. Epithelial antimicrobial peptides in host defense against infection. Respir Res 2000, 1, 141-150

Fellermann, K.; Stange, E.F. Defensins—Innate immunity at the epithelial frontier. Eur J Gastroenterol Hepatol 2001, 13, 771-776.

Stone, K.D.; Prussin, C.; Metcalfe, D.D. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2010, 125 (Suppl 2), S73–80.

Cooper, M.A, Colonna, M.; Yokoyama, W.M. Hidden talents of natural killers: NK cells in innate and adaptive immunity. EMBO Rep 2009, 10, 1103–1110, [PubMed: 19730434].

Soudja, S. M. H.; Chandrabos, C.; Yakob, E.; Veenstra, M.; Palliser, D.; Lauvau, G. Memory-T-Cell-Derived Interferon-? Instructs Potent Innate Cell Activation for Protective Immunity". Immunity 2014, 40 (6), 974–988.

Hoffmann, J. A.; Kafatos, F.C.; Janeway, C. A.; Ezekowitz, R.A. Phylogenetic Perspectives in Innate Immunity. Sci 1999, 284,

Turvey, S.E.; Broide, D.H. Innate immunity. J Allergy Clin Immunol 2010, 125(Suppl 2), S24–32.

Colloquium on Clinical Immunology, 1982

Diefenbach, A.; Raulet, D.H. Innate immune recognition by stimulatory immunoreceptors. Curr Opin Immunol 2003, 15, 37-44.

Gallucci, S.; Matzinger, P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001, 13, 114-119.

Gordon, S. Pattern recognition receptors: Doubling up for the innate immune response. Cell 2002,111, 927–930.

Beutler, L.E.; Clarkin, J.F.; Bongar, B. Guidelines for the systematic treatment of the depressed patient. New York: Oxford University Press 2000.

Fraser C.M.; Norris, S.J.; Weinstock, G.M.; White, O.; Sutton, G.G.; Dodson, R.; Gwinn, M.; Hickey, E.K.; Clayton, R.; Ketchum, K.A.; Complete genome sequence of Treponema pallidum, the syphilis spirochete. Science 1998, 281, 375-388.

Medzhitov, R.; Janeway, C.Jr. The Toll receptor family and microbial recognition. Trends Microbiol 2000b, 8, 452-456.

Shizuo, Akira; Kiyoshi, Takeda; Tsuneyasu, Kaisho. Toll-like Receptors: Critical Proteins Linking Innate and Acquired Immunity. Nat. Immuno 2001.

Vasselon, T.; Hanlon, W.A.; Wright, S.D.; Detmers, P.A. Toll-like receptor 2 (TLR2) mediates activation of stress-activated MAP kinase p38. J. Leukoc. Biol 2002.

Stahl, P.D.; Ezekowitz, R.A. The mannose receptor is a pattern recognition receptor involved in host defense. Curr Opin Immunol 1998, 10:50-55.

Barrington, R.; Zhang, M.; Fischer, M.; Carroll, M.C. The role of complement in inflammation and adaptive immunity. Immunol Rev 2001, 180, 5-15.

Borrow P. Mechanisms of viral clearance and persistence. J Viral Hepat 1997, 4, (Suppl 2), 16-24.

Grey, H.M.; Chestnut, R. Antigen processing and presentation to T cells. Immunology Today 1985, 6(3), 101-106.

Medzhitov, R.; Janeway, C.A.Jr. Innate immune induction of the adaptive immune response. Cold Spring Harb Symp Quant Biol 1999, 64, 429-435.

Murphy, K.M.; Travers, P.; Walport, M. Janeway’s immunobiology. 7th ed. New York: Garland Science 2007.

Alberts, B.; et al. The Adaptive Immune System. In Molecular Biology of the Cell. New York: Garland Science 2002. https://www.ncbi.nlm.nih.gov/books/NBK21070/ Accessed August 2, 2018.

Bonilla, F.A.; Oettgen, H.C. Adaptive immunity. J Allergy Clin Immunol 2010, 125(Suppl 2), S33–40.

Craft, J. The adaptive immune system. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier Saunders, 2016, 46.

Den, Haan; Joke, M.M.; Arens, Ramon; Zelm, Menno; Van, C. The activation of the adaptive immune system: Cross-talk between antigen-presenting cells, T cells and B cells". Immunology Letters 2014, 162 (2), 103–112. Doi:10.1016/j.imlet.2014.10.011. PMID 25455596.

Knight, S.C.; Stagg, A.J. Antigen-presenting cell types. Curr Opin Immunol 1993, 5, 374-382.

Blum, J.S.; Ma, C.; Kovats, S. Antigen-presenting cells and the selection of immunodominant epitopes. Crit Rev Immunol 1997, 17, 411-417.

Blackwell, J, M.; Jamieson, S.E.; Burgner, D. HLA and infectious diseases. Clin Microbiol Rev 2009; 22:370–85. https://doi.org/10.1128/CMR.00048-08

Medzhitov, R.; Janeway, C. Jr. The Toll receptor family and microbial recognition. Trends Microbiol 2000b, 8, 452-456.

Burnet, F.M. The Clonal Selection Theory of Acquired Immunity. Cambridge: Cambridge University Press 1959.

Crotty, S.; Ahmed, R. Immunological memory in humans. Semin Immunol 2004, 16, 197-203.

Mbongue, Jacques; Nicholas, Dequina; Firek, Anthony; Langridge, William. The Role of Dendritic Cells in Tissue-Specific Autoimmunity". Journal of Immunology 2014, 04, 30.

Le Bon, A.; Tough, D.F. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 2002, 14, 432-436.

Bedoui, S.; Gebhardt, T.; Gasteiger, G.; Kastenmuller, W. Parallels and differences between innate and adaptive lymphocytes. Nat Immunol 2016, 17, 490–494.

Unanue, E.R. Antigen-presenting function of the macrophage. Annual Review of Immunology 1984, 2, 395-428.

Borrow, P.; Shaw, G.M. Cytotoxic T-lymphocyte escape viral variants: How important are they in viral evasion of immune clearance in vivo? Immunol Rev 1998, 164:37-51.

Holtmeier, W.; Kabelitz, D. Gamma delta T cells link innate and adaptive immune responses. Chem Immunol Allergy 2005, 86, 151- 83.

Stutman, O. Intra thymic and extrathymic T cell maturation. Immunol Rev 1978, 42, 138-84.

Townsend, A.; Bodmer, H. Antigen recognition by class I-restricted T lymphocytes. Annual Review of Immunology 1989; 7, 601-624

Tangye, S.G.; Tarlinton, D.M. Memory B cells: effectors of long-lived immune responses. Eur J Immunol 2009, 39, 2065–2075. [PubMed: 19637202].

Jiang, H.; Chess, L. An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest 2004, 114(9), 1198-208.

Wing, K.; Sakaguchi, S. Regulatory T cells exert checks and balances on self-tolerance and autoimmunity. Nat Immunol 2010, 11, 7–13.

Bhagavan, N.V.; Chung-Eun, Ha. In Essentials of Medical Biochemistry 2011.

Germain, R.N. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994, 76, 287-99.

Sonderstrup, G.; McDevitt HO, D.R.; DQ, and you. MHC alleles and autoimmunity. J Clin Invest 2001, 107,795–796, [PubMed: 11285296].

Zinkernagel, R.M.; Doherty, P.C. MHC-restricted cytotoxic T cells: Studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv Immunol 1979, 27, 51-177.

Konig, R.; Fleury, S.; Germain, R.N. The structural basis of CD4-MHC class II interactions: Co-receptor contributions to T cell receptor antigen recognition and oligomerization-dependent signal transduction. Curr Top Microbiol Immunol 1996, 205, 19–46. [PubMed: 8575196].

Hunter, C.A.; Reiner, S.L. Cytokines and T cells in host defense. Curr Opin Immunol 2000, 12, 413-418.

Van Kaer, L. Accessory proteins that control the assembly of MHC molecules with peptides. Immunol Res 2001, 23, 205–214, [PubMed: 11444385].

Croft, M.; Carter, L.; Swain, S.L.; Dutton, R.W. Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med, 1994, 180: 1715–1728.

Atkinson, E.A.; Bleackley, RC. Mechanisms of lysis by cytotoxic T cells. Crit Rev Immunol 1995, 15, 359-384.

Rudin, C.M.; Thompson, C.B. B-Cell Development and Maturation. Seminar in Oncology 1998, 25(4), 435-46.

McHeyzer-W.; M.G. B cells as effectors. Curr Opin Immunol 2003, 15(3), 354-61.

Gray, D. A role for antigen in the maintenance of immunological memory. Nat Rev Immunol 2002, 2:60-65.

Larsson, Lars-Inge. Immunocytochemistry: Theory and practice. Crc Press 1988, 1, ISBN 0-8493-6078-1.

Flanagan, R.J.; Jones A.L. Fab antibody fragments: some applications in clinical toxicology. Drug Saf 2004, 27 (14), 1115–1133. Doi: 10.2165/00002018-200427140-00004. PMID 15554746.

Finkelman, F.D.; Holmes, J.; Katona, I.M.; Urban, J.F.; Jr.; Beckman, M.P.; Schooley, K.A.;Coffman, R.L.; Mosmann, T.R.; Paul, W.E.; Lymphokine control of in vivo immunoglobulin isotype selection. Annu.Rev.Immunol 1990, 8, 303.

Pulendran, B.; Palucka, K.; Banchereau, J. Sensing pathogens and tuning immune responses. Science 2001, 293, 253-256.

Schroeder, H.W.; Cavacini, L. Structure and function of immunoglobulins. J Allergy Clin Immunol, 2010, 125 (Suppl 2), S41–52.

Abbas, A.K.; Lichtman, A.H.; Pillai, S. Cellular and Molecular Immunology, 6a ed, Editora Saunders 2007.

Vojdani, A.; Erde, J. Regulatory T cells, a potential immunoregulatory target for CAM researchers: Modulating tumor immunity, autoimmunity and alloreactive immunity (III). Evid Based Complement Alternat Med (eCAm) 2006, 3, 309-316.

Janeway, C.A.; and Jr. The Humoral Immune Response.” Immunobiology: The Immune System in Health and Disease. 5th edition. U.S. National Library of Medicine, 1970, Available here. Accessed 20 Sept. 2017.

Mills, C.D.; Kincaid K.; Alt, J.M.; Heilman, M.J.; Hill, A.M. M-1/M-2 Macrophages and the Th1/Th2 Paradigm. J. Immunol. 2000, 164, 6166–6173, doi: 10.4049/jimmunol.164.12.6166.

Smith, JA. Neutrophils, host defense, and inflammation: a double-edged sword. J Leukoc Biol, 1994, 56, 672–86.

Kita H. The eosinophils: a cytokine-producing cells? J Allergy Clin Immunol 1996, 97, 889–892.

Galli, S.J. Mast cells and basophils. Curr Opin Hematol, 2000, 7, 32-39.

Amin, K.; Ludviksdottir, D.C.; Janson, O.; Nettelbladt, E.; Bjornsson, G.M.; Roomans, G.; Boman, L.; Seveus, P. Venge Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR group Am J Respir Crit Care Med, 2000, 162, 2295-2301.

Gershon, RK.; Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 1970, 18, 723–37.

Saha, P.; Geissmann, F. Toward a functional characterization of blood monocytes. Immunol Cell Biol 2010; 89, 2–4.

Carrega, P.; Ferlazzo, G. Natural killer cell distribution and trafficking in human tissues. Front Immunol 2012, 3, 347. Doi: 10.3389/fimmu 2012, 00347.

Spits, H: Development of alpha beta T cells in the human thymus. Nat Rev Immunol 2002, 2: 760-772.

Hardy, R.R.; Hayakawa, K. B. Cell development pathways. Annu Rev Immunol 2001, 19, 595–621. 10.1146/annurev.immunol.19.1.595.

Jia, Liu.; Ruiyuan, Cao.; Mingyue, Xu.; Xi, Wang.; Huanyu, Zhang.; et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery 2020, 6, 16.

Xu, H.; et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int. J. Oral. Sci 2020, 12, 8.

Hamming, I.; et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol 2004, 203, 631–637.

Zhou, P.; et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020, 579, 270–273.

Zhao, Y.; et al. Single- cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019- nCov. Preprint at bioRxiv 2020, https://doi.org/10.1101/2020.01.26.919985

Walls, A. C.; et al. Structure, function, and antigenicity of the SARS- CoV-2 spike glycoprotein. Cell 2020. https://doi.org/10.1016/j.cell.2020.02.058

Jacobs, R.F.; Tabor, D.R.; Burks, A.W.; Campbell, G.D. Elevated interleukin-1 release by human alveolar macrophages during the adult respiratory distress syndrome. Am. Rev. Respir. Dis 1989. 140, 1686–1692. https://doi.org/10.1164/ajrccm/140.6.1686.

Pison, U.; Brand, M.; Joka, T.; Obertacke, U.; Bruch. J. Distribution and function of alveolar cells in multiply injured patients with trauma induced ARDS. Intensive Care Med, 1988, 14, 602–609. https://doi.org/10.1007/BF0025676

Kuipers, M.T.; van der Poll, T.; Schultz, M.J.; Wieland C.W. Benchto- bedside review: Damage-associated molecular patterns in the onset of ventilator-induced lung injury. Crit. Care 2011, 15:235. https://doi.org/10.1186/cc10437

Diebold, S.S.; Kaisho, T.; Hemmi, H.; Akira, S.; Reis e Sousa, C. Innate antiviral responses by means of TLR7-mediated recognition of single stranded RNA. Science 2004, 303, 1529–1531. https://doi.org/10.1126/science.1093616

Imai, Y.; Kuba, K.; Neely, G.G.; Yaghubian-Malhami, R.; Perkmann, T.; van Loo, G.; Ermolaeva, M.; Veldhuizen, R.; Leung, Y.H.; Wang, H.; et al. 2008. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008,133, 235–249. https://doi.org/10.1016/j.cell.2008.02.043

Medzhitov, R.; Preston-H.P.; Janeway, C.A.; J.r. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature, 1997, 388, 394-7.

Martinon, F.; Burns, K.; Tschopp, J.; The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 2002, 10, 417–426. https://doi.org/10.1016/S1097-2765(02)00599-3

Zhang, B.; et al. Clinical characteristics of 82 death cases with COVID-19. Preprint at medRxiv 2020, https://doi. org/10.1101/2020.02.26.20028191

Wen, W.; Su, W.; Tang, H.; Le, W.; Zhang, X.; Zheng, Y.; Liu, X.; Xie, L.; Li, J.; Ye, J.; et al. Immune Cell Profiling of COVID-19 Patients in the Recovery Stage by Single-Cell Sequencing. medRxiv 2020, 2020.03.23.20039362.

Tian, S.; et al. Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J. Thorac. Oncol 2020. https://doi.org/10.1016/j.jtho.2020.02.010

Harker, J.A.; Lewis, G.M.; Mack, L.; Zuniga. E.I. Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection. Science 2011.334:825–829. https://doi.org/10.1126/science.1208421

Chen, L.; Liu, H.G.; Liu, W.; Liu, J.; Liu, K.; Shang, J.; et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi, 2020, 43, 203–8.

Grupp, S.A.; Kalos, M.; Barrett, D.; Aplenc, R.; Porter, D.L.; Rheingold, S.R.; Teachey, D.T.; Chew, A.; Hauck, B.; Wright, J.F. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med 2013. 368:1509–1518. https://doi.org/10.1056/NEJMoa1215134.

Mehta, P.; McAuley, D.F.; Brown, M.; Sanchez, E.; Tattersall, R.S.; Manson, J.J. Hlh Across Speciality Collaboration, U. K. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020, 395, 1033–1034.

Diao, B.; Wang, C.; Wang, R.; Feng, Y.; Tan, Z.; Wang, H.; Wang, C.; Liu, L.; Liu, Y.; Liu, Y.; et al. Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. medRxiv 2020b. https://doi.org/10.1101/2020.03.04.20031120.

Yao, X.; Ye, F.; Zhang, M.; Cui, C.; Huang, B.; Niu, P.; et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020.

Ahmed, R.; Salmi, A.; Butler, L.D.; Chiller, J.M.; Oldstone, M.B. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J. Exp. Med 1984,160, 521–540.https://doi.org/10.1084/jem.160.2.521.

Wong, R.S.; et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ 2003, 326, 1358–1362.

Cui, W.; et al. Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome. Clin. Infect. Dis 2003, 37, 857–859.

Li, T.; et al. Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J. Infect. Dis 2004, 189, 648–651.

Zheng, H. Y.; et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell. Mol. Immunol 2020. https://doi.org/10.1038/s41423-020-0401-3

Thevarajan, I. et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non- severe COVID-19. Nat. Med 2020. https://doi.org/10.1038/s41591-020-0819-2

Nie, Y.; et al. Neutralizing antibodies in patients with severe acute respiratory syndrome- associated coronavirus infection. J. Infect. Dis 2004, 190, 1119–1126.

Temperton, N. J.; et al. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg. Infect. Dis 2005, 11, 411–416.

Haveri, A.; Smura, T.; Kuivanen, S.; Österlund, P.; Hepojoki, J.; Ikonen, N.; Pitkäpaasi, M.; Blomqvist, S.; Rönkkö, E.; Kantele, A.; et al. Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February. Eurosurveillance, 2020, 25, 2000266.

Lou, B.; Li, T.; Zheng, S.; Su, Y.; Li, Z.; Liu, W.; Yu, F.; Ge, S.; Zou, Q.; Yuan, Q.; et al. Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset. medRxiv 2020, 2020.03.23.20041707.

Okba, N.M.A.; Muller, M.A.; Li, W.; Wang, C.; Geurtsvan, K.C.H.; Corman, V.M.; Lamers, M.M.; Sikkema, R.S.; de Bruin, E.; Chandler, F.D.; et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients. Emerg. Infect. Dis 2020, 26.

Tan, W.; Lu, Y.; Zhang, J.; Wang, J.; Dan, Y.; Tan, Z.; He, X.; Qian, C.; Sun, Q.; Hu, Q.; et al. Viral Kinetics and Antibody Responses in Patients with COVID-19. medRxiv 2020b, 2020.03.24.20042382.

Wölfel, R.; Corman, V.M.; Guggemos, W.; Seilmaier, M.; Zange, S.; Müller, M.A.; Niemeyer, D.; Jones, T.C.; Vollmar, P.; Rothe, C.; et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020.

Wu, F.; Wang, A.; Liu, M.; Wang, Q.; Chen, J.; Xia, S.; Ling, Y.; Zhang, Y.; Xun, J.; Lu, L.; et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv 2020b. 2020.03.30.20047365.

Zhao, J.; Yuan, Q.; Wang, H.; Liu, W.; Liao, X.; Su, Y.; Wang, X.; Yuan, J.; Li, T.; Li, J.; et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis. 2020a.

Amanat, F.; Nguyen, T.; Chromikova, V.; Strohmeier, S.; Stadlbauer, D.; Javier, A.; Jiang, K.; Asthagiri-Arunkumar, G.; Polanco, J.; Bermudez-Gonzalez, M.; et al. A serological assay to detect SARSCoV-2 seroconversion in humans. medRxiv 2020, 2020.03.17.20037713.

Ju, B.; Zhang, Q.; Ge, X.; Wang, R.; Yu, J.; Shan, S.; Zhou, B.; Song, S.; Tang, X.; Yu, J.; et al. Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. bioRxiv 2020, 2020.03.21.990770.

To, K.K.W.; Tsang, O.T.Y.; Leung, W.S.; Tam, A.R.; Wu, T.C.; Lung, D.C.; Yip, C.C. Y.; Cai, J.P.; Chan, J.M.C.; Chik, T.S.H.; et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis 2020.

Browning, D.J. Hydroxychloroquine and chloroquine retinopathy. Springer 2014. [ISBN:9781493905973].

Jia, Liu.; Ruiyuan, Cao.; Mingyue, Xu.; Xi, Wang.; Huanyu, Zhang.; et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery 2020, 6:16.

Devaux, CA.; Rolain, J.M.; Colson, P.; Raoult, D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020 11:105938. https://doi.org/10.1016/j.ijantimicag.2020.105938

Circu, M.; et al. Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non- small-cell lung cancer cells. PLoS One 2017, 12, e0184922.

Mauthe, M.; et al. Chloroquine inhibits autophagic flux by decreasing autophagosome- lysosome fusion. Autophagy, 2018, 14, 1435–1455.

Frustaci, A.; et al. Inhibition of cardiomyocyte lysosomal activity in hydroxychloroquine cardiomyopathy. Int. J. Cardiol 2012, 157, 117–119.

Sundelin, S.P.; Terman, A. Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. APMIS 2002,110, 481–489.

Ballabio, A.; Bonifacino J.S. Lysosomes as dynamic regulators of cell and organismal homeostasis. Nat. Rev. Mol. Cell Biol 2019, 21, 101–118.

Lotteau, V.; et al. Intracellular transport of class II MHC molecules directed by invariant chain. Nature 1990, 348, 600–605.

Ghislat, G.; Lawrence, T. Autophagy in dendritic cells. Cell Mol. Immunol, 2018, 15, 944–952.

Munz, C. Autophagy beyond intracellular MHC class II antigen presentation. Trends Immunol. 2016, 37, 755–763.

Ireland, J.M.; Unanue, E.R. Autophagy in antigen- presenting cells results in presentation of citrullinated peptides to CD4 T cells. J. Exp. Med 2011, 208, 2625–2632.

Ohkuma, S.; Poole, B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc. Natl Acad. Sci. USA 1978, 75, 3327–3331.

Rebecca, V.W.; et al. PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov 2019, 9, 220–229.

Ma, C.; et al. Identifying key genes in rheumatoid arthritis by weighted gene co- expression network analysis. Int. J. Rheum. Dis 2017, 20, 971–979.

Ewald, S.E.; et al. The ectodomain of Toll- like receptor 9 is cleaved to generate a functional receptor. Nature 2008, 456, 658–662.

Kuznik, A.; et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J. Immunol 2011, 186, 4794–4804.

Hacker, H.; et al. CpG- DNA-specific activation of antigen- presenting cells requires stress kinase activity and is preceded by non- specific endocytosis and endosomal maturation. EMBO J 1998, 17, 6230–6240.

Lau, C.M.; et al. RNA- associated autoantigens activate B cells by combined B cell antigen receptor/Toll- like receptor 7 engagement. J. Exp. Med 2005, 202, 1171–1177.

Vollmer, J.; et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll- like receptors 7 and 8. J. Exp. Med 2005, 202, 1575–1585.

An, J.; et al. Antimalarial drugs as immune modulators: new mechanisms for old drugs. Annu. Rev. Med 2017, 68, 317–330.

Zhang, X.; et al. The cytosolic DNA sensor cGAS forms an oligomeric complex with DNA and undergoes switch- like conformational changes in the activation loop. Cell Rep 2014, 6, 421–430.

Zhang, X.; et al. Cyclic GMP- AMP containing mixed phosphodiester linkages is an endogenous high- affinity ligand for STING. Mol. Cell 2013, 51, 226–235.

Shu, C.; Li, X.; Li, P. The mechanism of double- stranded DNA sensing through the cGAS- STING pathway. Cytokine Growth Factor Rev 2014, 25, 641–648.

An, J.; et al. Cutting edge: antimalarial drugs inhibit IFN- ? production through blockade of cyclic GMP- AMP synthase- DNA interaction. J. Immunol 2015, 194, 4089–4093.

Van den Borne, B.E.; et al. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor- alpha, interleukin 6, and interferon- gamma production by peripheral blood mononuclear cells. J. Rheumatol 1997, 24, 55–60.

Wallace, D.J.; et al. The effect of hydroxychloroquine therapy on serum levels of immunoregulatory molecules in patients with systemic lupus erythematosus. J. Rheumatol 1994, 21, 375–376.

Wallace, D.J.; et al. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 1993, 2, S13–S15.

Hjorton, K.; et al. Cytokine production by activated plasmacytoid dendritic cells and natural killer cells is suppressed by an IRAK4 inhibitor. Arthritis Res. Ther 2018, 20, 238.

Willis, R.; et al. Effect of hydroxychloroquine treatment on pro- inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multi ethnic US cohort. Lupus 21, 2012, 830–835.

Klinefelter, H. F.; Achurra, A. Effect of gold salts and antimalarials on the rheumatoid factor in rheumatoid arthritis. Scand. J. Rheumatol 1973, 2, 177–182.

Dixon, J.S.; et al. Biochemical indices of response to hydroxychloroquine and sodium aurothiomalate in rheumatoid arthritis. Ann. Rheum 1981, 40, 480–488.

Wu, S. F.; et al. Hydroxychloroquine inhibits CD154 expression in CD4(+) T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signalling. Arthritis Res. Ther 2017,19, 183.

Qushmaq, N. A.; Al- Emadi, S.A. Review on effectiveness of primary prophylaxis in aPLs with and without risk factors for thrombosis: efficacy and safety. ISRN Rheumatol 2014, 348726.

Nuri, E.; et al. Long- term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol. Res 2017, 65, 17–24.

Dadoun, S.; et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta- analysis. Joint Bone Spine. 2013, 80, 29–33.

Van den Hoek, J.; et al. Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatol. Int 2017, 37, 487–493.

Avina- Zubieta, J. A.; et al. Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: a general population-based study. Arthritis Care Res 2017, 69, 849–856.

Tselios, K.; Gladman, D.D.; Su, J.; Ace, O.; Urowitz, M.B. Evolution of risk factors for atherosclerotic cardiovascular events in systemic lupus erythematosus: a long-term prospective study. J. Rheumatol 2017, 44,1841–1849.

Padol, I. T.; Hunt, R.H. Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence- based interpretation. Rheumatology 2010, 49, 837–843.

Hage, M.P.; Al- Badri, M.R.; Azar, S.T. A favourable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti- inflammatory role. Ther. Adv. Endocrinol. Metab. 2014, 5, 77–85.

Cansu, D.U.; Korkmaz, C. Hypoglycaemia induced by hydroxychloroquine in a non- diabetic patient treated for RA. Rheumatology 2008, 47, 378–379.

Fasano, S.; et al. Long term hydroxychloroquine therapy and low- dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. J. Rheumatol 2017,44, 1032–1038.

Towers, C.G.; Thorburn, A. Therapeutic targeting of autophagy. E.Bio.Medicine 2016, 14, 15–23.

Rand, J.H.; et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody- ?2-glycoprotein I complexes to phospholipid bilayers. Blood 2008,112, 1687–1695.

Jancinova, V.; Nosal, R.; Petrikova, M. On the inhibitory effect of chloroquine on blood platelet aggregation. Thromb. Res 1994,74, 495–504.

Bertrand, E.; et al. Anti-aggregation action of chloroquine. Med. Trop 1990, 50, 143–146.

Nosal, R.; Jancinova, V.; Petrikova, M. Chloroquine inhibits stimulated platelets at the arachidonic acid pathway. Thromb. Res 1995, 77, 531–542.

Biot, C.; Daher, W.; Chavain, N.; Fandeur, T.; Khalife, J.; Dive, D.; et al. Design and synthesis of hydroxy ferroquine derivatives with antimalarial and antiviral activities. J Med Chem 2006, 49, 2845–9.

Laaksonen, A.L.; Koskiahde, V.; Juva, K. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine. Scand. J. rheumatol 1974, 3, 103–108.

Philippe, Gautret, Jean C.; Lagier, Philippe, P.; Van, T.H.; Line, M.; et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial. Journal of Antimicrobial agents 2020. https://doi.org/10.1016/j.ijantimicag.2020.105949

Awadhesh, K.S.; Akriti, S.; Altamash, S.; Ritu, S.; Anoop M. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020, 14:241-246.

Rolain, J.M.; Colson, P.; Raoult, D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 2007, 30 (4), 297–308.

Mingo, R.M.; et al. Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endo lysosomes is a rate-defining step. J. Virol. 2015,89, 2931–2943.

Schrezenmeier, E.; Dorner, T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020, 16:155–66.

Al-Bari, M.A. Chloroquine analogues in drug discovery: New directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J. Antimicrob. Chemother. 2015, 70, 1608–1621.

US Food and Drug Administration (FDA). Emergency use authorization: Therapeutics. Maryland: FDA, 2020 (accessed 6 April 2020). https://www.fda.gov/emergency-preparedness-and-response

Treatment of COVID-19: Hydroxychloroquine and Chloroquine. Reports from the Congressional Research Service 2020. https://crsreports.congress.gov/product/pdf/IN/IN11347

European Medicines Agency, 2020. EMA/170590/2020. www.ema.europa.eu/contact

Indian council of medical research. Department of health research Ministry of health and family welfare government of India. D.O.No.VIR/4/2020/ECD-1.

https://globalregulatorypartners.com/anvisa-clarifies-on-use-of-chloroquine-and-hydroxychloroquine-as-potential-treatments-of-covid-19

Therapeutic Goods Administration. New restrictions on prescribing hydroxychloroquine for COVID-19. Canberra: Australian Government Department of Health, 2020. https://www.tga.gov.au/alert/new-restrictions-prescribing-hydroxychloroquine-covid-19

https://pharmafield.co.uk/pharma_news/chloroquine-and-hydroxychloroquine-not-licensed-for-coronavirus-treatment/